BioStem Technologies, Inc., a regenerative medicine company specializing in perinatal tissue allograft products, has filed its audited consolidated financial statements for the fiscal years ended December 31, 2024 and 2025. The documents are available for review on the OTC Markets website. This publication represents a crucial milestone as the company progresses toward an uplisting to the Nasdaq stock exchange.
Jason Matuszewski, Chairman and CEO of BioStem Technologies, stated that the achievement, combined with recent appointments of a new CFO, auditor, and audit committee chair, demonstrates the establishment of robust financial reporting processes. He emphasized that listing on Nasdaq remains a top priority, as it would increase the company's visibility, improve stock liquidity, provide a more precise market valuation, and enhance its ability to attract top talent.
BioStem Technologies focuses on developing, manufacturing, and commercializing advanced allograft solutions using proprietary processing technologies such as BioRetain®, CryoTek®, and SteriTek®. These technologies are designed to preserve the natural properties of perinatal tissues for clinical use. The company's quality management system and standard operating procedures have been accredited by the American Association of Tissue Banks and comply with current Good Tissue Practices and current Good Manufacturing Processes.
The company's product portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ brands, which are utilized by clinicians across various medical specialties. For more information about the company, visit biostemtechnologies.com. The latest news and updates relating to the company are available in its newsroom at https://tinyurl.com/bsemnewsroom.
The announcement includes forward-looking statements regarding the company's expectations for financial and operational strength, the benefits of acquired assets, navigating reimbursement landscapes, executing operational strategies, uplisting to Nasdaq, first quarter 2026 financial results, and product growth and market penetration. These statements are subject to risks and uncertainties, including changes in reimbursement levels, competition, technological changes, physician adoption, marketing effectiveness, accounting treatments, financing availability, historical losses, regulatory changes, production capacity, and general economic factors.
